Philip Gregory, bluebird bio, Inc. (BLUE)’s insider Sold 2,250 Shares; Lansdowne Partners Uk Llp Has Decreased By $2.09 Million Its Alibaba Group Hldg LTD (BABA) Position

Lansdowne Partners Uk Llp decreased Alibaba Group Hldg Ltd (BABA) stake by 24.23% reported in 2017Q3 SEC filing. Lansdowne Partners Uk Llp sold 12,134 shares as Alibaba Group Hldg Ltd (BABA)’s stock rose 22.58%. The Lansdowne Partners Uk Llp holds 37,944 shares with $6.55M value, down from 50,078 last quarter. Alibaba Group Hldg Ltd now has $463.21 billion valuation. The stock decreased 3.62% or $6.78 during the last trading session, reaching $180.53. About 30.72 million shares traded or 46.74% up from the average. Alibaba Group Holding Limited (NYSE:BABA) has risen 57.33% since February 5, 2017 and is uptrending. It has outperformed by 40.63% the S&P500.

Transaction amounting to approximately $461,020 U.S Dollars was made public in a legal form submitted to the Security Exchange Commission on February 05, 2018. According to which, Philip Gregory, the Chief Scientific Officer of Bluebird Bio Inc also an insider of the Massachusetts-based company had sold exactly 2,250 shares – ( at $204.9 for each share ). Philip is trying to silently decrease his company’s share, same as he did in the last month. He unloaded another 3,962 shares worth $703,370 USD. Philip Gregory owns 0.06% of the -company’s market cap or 31,272 shares.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $9.50 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

The stock decreased 3.32% or $6.6 during the last trading session, reaching $192.3. About 1.01M shares traded or 6.34% up from the average. bluebird bio, Inc. (NASDAQ:BLUE) has risen 112.34% since February 5, 2017 and is uptrending. It has outperformed by 95.64% the S&P500.

Among 25 analysts covering bluebird bio (NASDAQ:BLUE), 14 have Buy rating, 2 Sell and 9 Hold. Therefore 56% are positive. bluebird bio has $309.0 highest and $14 lowest target. $165.68’s average target is -13.84% below currents $192.3 stock price. bluebird bio had 81 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Friday, June 23 with “Sell”. Zacks downgraded the stock to “Buy” rating in Tuesday, August 11 report. The rating was downgraded by Standpoint Research on Friday, June 16 to “Reduce”. Oppenheimer maintained bluebird bio, Inc. (NASDAQ:BLUE) on Tuesday, January 9 with “Hold” rating. The firm has “Buy” rating given on Tuesday, July 4 by Jefferies. The rating was maintained by Roth Capital with “Buy” on Friday, August 28. The rating was maintained by BTIG Research on Thursday, August 3 with “Hold”. The rating was initiated by Stifel Nicolaus with “Buy” on Thursday, December 17. The rating was downgraded by Roth Capital to “Neutral” on Monday, February 6. The firm has “Hold” rating by Cantor Fitzgerald given on Friday, June 3.

Since August 7, 2017, it had 0 buys, and 28 selling transactions for $56.91 million activity. Gregory Philip D also sold $74,250 worth of bluebird bio, Inc. (NASDAQ:BLUE) on Monday, August 7. 25,000 bluebird bio, Inc. (NASDAQ:BLUE) shares with value of $4.90M were sold by Cole Jason. 13,839 shares were sold by MARAGANORE JOHN, worth $1.33M. Walsh Jeffrey T. sold 1,250 shares worth $133,826. 6,000 shares were sold by Davidson David, worth $1.08 million. 500 shares were sold by LYNCH DANIEL, worth $60,000 on Thursday, August 31. $95,950 worth of bluebird bio, Inc. (NASDAQ:BLUE) was sold by Mandell James.

Investors sentiment increased to 1.79 in 2017 Q3. Its up 0.11, from 1.68 in 2017Q2. It improved, as 35 investors sold bluebird bio, Inc. shares while 42 reduced holdings. 45 funds opened positions while 93 raised stakes. 49.05 million shares or 2.37% more from 47.91 million shares in 2017Q2 were reported. Swiss Bank & Trust reported 0.01% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Moreover, Benjamin F Edwards & Comm has 0% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 44 shares. Kentucky-based Teachers Retirement Of The State Of Kentucky has invested 0.05% in bluebird bio, Inc. (NASDAQ:BLUE). Cormorant Asset Mngmt Lc reported 137,500 shares. California State Teachers Retirement reported 0.02% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Westpac Banking Corp has 27,792 shares for 0.08% of their portfolio. Bancorporation Of Ny Mellon holds 245,563 shares. Amalgamated Bank holds 0.02% or 5,735 shares. Fmr Limited Liability reported 0.11% in bluebird bio, Inc. (NASDAQ:BLUE). Nuveen Asset Ltd invested in 0% or 3,454 shares. Next Financial Gru stated it has 0% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Parametric Portfolio Assoc Limited Liability holds 0% or 27,469 shares. Susquehanna Interest Grp Limited Liability Partnership reported 164,934 shares or 0.01% of all its holdings. Credit Suisse Ag reported 105,331 shares. Cornerstone Capital Ltd Liability reported 16,855 shares.

Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on February, 28. They expect $-1.63 EPS, up 13.30% or $0.25 from last year’s $-1.88 per share. After $-1.73 actual EPS reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts -5.78% EPS growth.

Among 38 analysts covering Alibaba (NYSE:BABA), 36 have Buy rating, 1 Sell and 1 Hold. Therefore 95% are positive. Alibaba had 167 analyst reports since August 12, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, November 3 by Brean Capital. On Monday, September 14 the stock rating was maintained by Axiom Capital with “Buy”. Morgan Stanley maintained it with “Buy” rating and $250.0 target in Monday, January 29 report. SunTrust maintained the stock with “Buy” rating in Thursday, November 2 report. The stock of Alibaba Group Holding Limited (NYSE:BABA) has “Buy” rating given on Friday, February 2 by Needham. The firm has “Overweight” rating by KeyBanc Capital Markets given on Friday, August 18. As per Thursday, February 1, the company rating was maintained by Robert W. Baird. Needham maintained it with “Buy” rating and $125 target in Thursday, October 20 report. Oppenheimer maintained it with “Outperform” rating and $220 target in Monday, November 6 report. The company was maintained on Friday, November 3 by Needham.

Lansdowne Partners Uk Llp increased United Technologies Corp (NYSE:UTX) stake by 98,684 shares to 172,389 valued at $20.01M in 2017Q3. It also upped Priceline Grp Inc (NASDAQ:PCLN) stake by 585 shares and now owns 3,735 shares. Eaton Corp Plc (NYSE:ETN) was raised too.